Cresco Labs Inc. (OTCMKTS:CRLBF) Receives $2.50 Average Price Target from Analysts

Shares of Cresco Labs Inc. (OTCMKTS:CRLBF) have earned an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating, two have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $2.50.

A number of brokerages recently commented on CRLBF. Cormark lowered shares of Cresco Labs from a “moderate buy” rating to a “hold” rating in a research note on Monday, November 11th. Atb Cap Markets lowered shares of Cresco Labs from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th. Finally, Roth Capital upgraded shares of Cresco Labs to a “strong-buy” rating in a research note on Sunday, November 10th.

Cresco Labs Stock Up 0.2 %

Shares of CRLBF opened at $0.88 on Wednesday. Cresco Labs has a 52 week low of $0.78 and a 52 week high of $2.60. The firm has a market cap of $430.30 million, a P/E ratio of -4.41 and a beta of 1.79. The firm’s 50-day simple moving average is $0.91 and its 200 day simple moving average is $1.27. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.39 and a current ratio of 1.97.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.